A detailed history of Orbimed Advisors LLC transactions in Rapt Therapeutics, Inc. stock. As of the latest transaction made, Orbimed Advisors LLC holds 13,135,260 shares of RAPT stock, worth $15.8 Million. This represents 0.56% of its overall portfolio holdings.

Number of Shares
13,135,260
Holding current value
$15.8 Million
% of portfolio
0.56%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

BUY
$0.81 - $3.1 $10.6 Million - $40.7 Million
13,135,260 New
13,135,260 $20.8 Million
Q4 2023

Feb 14, 2024

SELL
$11.28 - $25.46 $10.9 Million - $24.5 Million
-963,532 Reduced 77.4%
281,413 $6.99 Million
Q3 2023

Nov 14, 2023

SELL
$16.34 - $24.66 $100,082 - $151,042
-6,125 Reduced 0.49%
1,244,945 $20.7 Million
Q3 2022

Nov 14, 2022

BUY
$17.96 - $30.46 $6.91 Million - $11.7 Million
384,674 Added 44.4%
1,251,070 $30.1 Million
Q2 2022

Aug 15, 2022

BUY
$10.26 - $23.59 $5.18 Million - $11.9 Million
505,096 Added 139.8%
866,396 $15.8 Million
Q1 2022

May 16, 2022

BUY
$17.02 - $40.22 $2.46 Million - $5.8 Million
144,300 Added 66.5%
361,300 $7.95 Million
Q4 2021

Feb 14, 2022

BUY
$29.5 - $39.5 $6.4 Million - $8.57 Million
217,000 New
217,000 $7.97 Million

Others Institutions Holding RAPT

About RAPT Therapeutics, Inc.


  • Ticker RAPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,656,600
  • Market Cap $35.6M
  • Description
  • RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that se...
More about RAPT
Track This Portfolio

Track Orbimed Advisors LLC Portfolio

Follow Orbimed Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Orbimed Advisors LLC with notifications on news.